Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran Switch vs Adjunctive Quetiapine in MDD
NCT02720198Phase 3Completed
- Sponsor
- Duke University
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of levomilnacipran in major depressive disorder (MDD) (2 arms), sponsored by Duke University. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Jan 2017; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02720198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720198.